HAIER BIOMEDICAL(SH:688139) Zheng Quan Ri Bao Wang·2025-10-31 02:49Core Viewpoint - Haier Biomedical has shown significant performance recovery in Q3 2025, driven by strong revenue growth and improved profitability, indicating a positive trend in the life sciences and medical device sectors as they transition towards international expansion and technological innovation [1][2]. Group 1: Financial Performance - In Q3 2025, Haier Biomedical achieved a revenue of 566 million yuan, representing a year-on-year increase of 1.24% and a quarter-on-quarter increase of 11.68% [1]. - The net profit attributable to shareholders reached 55.65 million yuan, with a quarter-on-quarter growth exceeding 70% [1]. - The non-recurring net profit was 49.99 million yuan, showing a quarter-on-quarter increase of over 100% [1]. Group 2: Industry Trends - The life sciences sector is entering a new phase of valuation recovery and industrial upgrading after a decade of development, supported by supply clearing, demand recovery, and accelerated domestic substitution [2]. - Haier Biomedical's performance recovery is attributed to revenue growth, business structure upgrades, and enhanced product competitiveness [2]. Group 3: Business Segments - The recovery in Q3 is supported by four key industries: low-temperature storage, smart medication, blood technology, and laboratory solutions, which have begun to show stable performance [3]. - New industries, particularly smart medication and blood technology, have demonstrated significant growth, contributing to approximately 48% of total revenue [3]. - The smart medication segment has established itself among the top three in the automated medication market by addressing hospital drug management challenges [3]. Group 4: Market Position and Innovation - The low-temperature storage segment continues to maintain a leading market share in China, with steady growth in revenue [4]. - Haier Biomedical's commitment to technological innovation is evident in its AI integration and the establishment of a multi-layered AI foundation, enhancing its product offerings and market responsiveness [5][6]. - The company reported a 20.18% year-on-year increase in overseas market revenue, reaching 634 million yuan, with successful localization strategies implemented in 18 countries [6].